Cohbarincwas A Clinical Stage Biotechnology Company Focused On Developing Mitochondria Based Therapeutics For Age Related Diseases And Metabolic Conditionsthe Company Aimed To Harness Mitochondrial Power To Create Innovative Treatments For Chronic Diseases With Limited Treatment Options Cohbar Specialized In Discovering And Developing Therapeutic Peptides Encoded Within The Mitochondrial Genomeits Pipeline Included Candidates Such As Cb5138 Ca For Fatty Liver Diseasecb4211 Targeting Metabolic Disorders Like Non Alcoholic Steatohepatitisnashand Obesityand Cb5138 3 For Fibrotic Diseasesthe Company Collaborated With Academic Institutions And Biotech Firms To Enhance Its Research And Expedite The Development Of Its Therapiescohbar Was Listed On Nasdaq Under The Ticker Cwbras Of 2023The Company Reported A Total Revenue Of $2 1 Million And A Cash Position Of $24 3 Million
